Intuitive Surgical
Price: 412.02Company and Business Model
Intuitive Surgical is a leader in robotic-assisted surgical systems, primarily known for its da Vinci Surgical System. The company develops and markets advanced surgical technologies, including instruments and accessories that enhance minimally invasive surgery. Its core revenue sources stem from system sales, instrument and accessory sales, and service agreements. The company operates mainly in the healthcare sector, focusing on improving surgical outcomes and patient recovery times.
Investment Profile
Intuitive Surgical's stock is more aligned with growth investors due to its focus on innovation and expanding market presence in robotic surgery. The absence of dividends and the current volatility suggest a higher risk profile, making it less suitable for conservative investors. The company is positioned for potential long-term growth, appealing to those willing to accept higher risk for future returns.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 8.37 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- -3.3% ↓
- EPS surprise
- 17.9% better than expected
- 20d volatility
- 2.5% stable
Forecast impact
negativeTrack in portfolio
Price chart
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-05-24 02:42 | Hold | Sell | Weak momentum and fundamentals suggest caution. |
| 2026-05-16 02:32 | Sell | Hold | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-08 14:59 | — | Sell | Weak momentum and fundamentals raise significant risk concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-02 12:24 | Piper Sandler | Update | — → 580 | 397.60999 |
| 2026-05-27 11:27 | Goldman Sachs | Target Lowered | 621 → 558 | 436.64 |
| 2026-04-23 10:18 | Barclays | Target Lowered | 712 → 651 | 483.62 |